Shenzhen Salubris Pharmaceuticals Co Ltd
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubit… Read more
Shenzhen Salubris Pharmaceuticals Co Ltd (002294) - Net Assets
Latest net assets as of September 2025: CN¥8.93 Billion CNY
Based on the latest financial reports, Shenzhen Salubris Pharmaceuticals Co Ltd (002294) has net assets worth CN¥8.93 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.98 Billion) and total liabilities (CN¥2.05 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.93 Billion |
| % of Total Assets | 81.31% |
| Annual Growth Rate | 27.75% |
| 5-Year Change | 56.52% |
| 10-Year Change | 86.39% |
| Growth Volatility | 116.17 |
Shenzhen Salubris Pharmaceuticals Co Ltd - Net Assets Trend (2006–2024)
This chart illustrates how Shenzhen Salubris Pharmaceuticals Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shenzhen Salubris Pharmaceuticals Co Ltd (2006–2024)
The table below shows the annual net assets of Shenzhen Salubris Pharmaceuticals Co Ltd from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.75 Billion | +8.65% |
| 2023-12-31 | CN¥8.06 Billion | +0.99% |
| 2022-12-31 | CN¥7.98 Billion | -0.86% |
| 2021-12-31 | CN¥8.05 Billion | +43.89% |
| 2020-12-31 | CN¥5.59 Billion | -16.12% |
| 2019-12-31 | CN¥6.67 Billion | -2.98% |
| 2018-12-31 | CN¥6.87 Billion | +11.57% |
| 2017-12-31 | CN¥6.16 Billion | +12.79% |
| 2016-12-31 | CN¥5.46 Billion | +16.28% |
| 2015-12-31 | CN¥4.70 Billion | +23.96% |
| 2014-12-31 | CN¥3.79 Billion | +20.84% |
| 2013-12-31 | CN¥3.13 Billion | +20.26% |
| 2012-12-31 | CN¥2.61 Billion | +22.11% |
| 2011-12-31 | CN¥2.13 Billion | +14.43% |
| 2010-12-31 | CN¥1.87 Billion | +14.91% |
| 2009-12-31 | CN¥1.62 Billion | +517.49% |
| 2008-12-31 | CN¥262.90 Million | +80.12% |
| 2007-12-31 | CN¥145.96 Million | +37.08% |
| 2006-12-31 | CN¥106.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shenzhen Salubris Pharmaceuticals Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 16451.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥5.09 Billion | 58.46% |
| Common Stock | CN¥1.11 Billion | 12.80% |
| Other Comprehensive Income | CN¥668.96 Million | 7.68% |
| Other Components | CN¥1.84 Billion | 21.06% |
| Total Equity | CN¥8.71 Billion | 100.00% |
Shenzhen Salubris Pharmaceuticals Co Ltd Competitors by Market Cap
The table below lists competitors of Shenzhen Salubris Pharmaceuticals Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nan Ya Printed Circuit Board Corp
TW:8046
|
$3.32 Billion |
|
Finning International Inc.
PINK:FINGF
|
$3.33 Billion |
|
QuantumScape Corporation Class A Common Stock
NYSE:QS
|
$3.33 Billion |
|
President Chain Store Corp
TW:2912
|
$3.33 Billion |
|
WPG Holdings Ltd
TW:3702
|
$3.32 Billion |
|
Liberty Global PLC Class B
NASDAQ:LBTYB
|
$3.32 Billion |
|
Discovery Silver Corp.
LSE:0A61
|
$3.32 Billion |
|
Bumrungrad Hospital Public Company Limited
PINK:BUHPF
|
$3.32 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shenzhen Salubris Pharmaceuticals Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,018,993,837 to 8,712,145,683, a change of 693,151,846 (8.6%).
- Net income of 601,569,148 contributed positively to equity growth.
- Dividend payments of 546,035,242 reduced retained earnings.
- Other comprehensive income increased equity by 34,226,092.
- Other factors increased equity by 603,391,848.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥601.57 Million | +6.9% |
| Dividends Paid | CN¥546.04 Million | -6.27% |
| Other Comprehensive Income | CN¥34.23 Million | +0.39% |
| Other Changes | CN¥603.39 Million | +6.93% |
| Total Change | CN¥- | 8.64% |
Book Value vs Market Value Analysis
This analysis compares Shenzhen Salubris Pharmaceuticals Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.08x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 341.73x to 7.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.16 | CN¥55.35 | x |
| 2007-12-31 | CN¥0.19 | CN¥55.35 | x |
| 2008-12-31 | CN¥0.34 | CN¥55.35 | x |
| 2009-12-31 | CN¥1.91 | CN¥55.35 | x |
| 2010-12-31 | CN¥1.78 | CN¥55.35 | x |
| 2011-12-31 | CN¥2.04 | CN¥55.35 | x |
| 2012-12-31 | CN¥2.49 | CN¥55.35 | x |
| 2013-12-31 | CN¥2.99 | CN¥55.35 | x |
| 2014-12-31 | CN¥3.63 | CN¥55.35 | x |
| 2015-12-31 | CN¥4.39 | CN¥55.35 | x |
| 2016-12-31 | CN¥5.11 | CN¥55.35 | x |
| 2017-12-31 | CN¥5.79 | CN¥55.35 | x |
| 2018-12-31 | CN¥6.35 | CN¥55.35 | x |
| 2019-12-31 | CN¥6.22 | CN¥55.35 | x |
| 2020-12-31 | CN¥5.36 | CN¥55.35 | x |
| 2021-12-31 | CN¥7.53 | CN¥55.35 | x |
| 2022-12-31 | CN¥7.23 | CN¥55.35 | x |
| 2023-12-31 | CN¥7.19 | CN¥55.35 | x |
| 2024-12-31 | CN¥7.82 | CN¥55.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shenzhen Salubris Pharmaceuticals Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.90%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.99%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.20x
- Recent ROE (6.90%) is below the historical average (20.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 32.16% | 16.85% | 1.28x | 1.49x | CN¥23.59 Million |
| 2007 | 50.11% | 20.93% | 1.37x | 1.75x | CN¥58.54 Million |
| 2008 | 44.48% | 22.18% | 1.29x | 1.55x | CN¥90.65 Million |
| 2009 | 13.31% | 25.39% | 0.48x | 1.09x | CN¥53.60 Million |
| 2010 | 19.07% | 27.38% | 0.60x | 1.17x | CN¥168.99 Million |
| 2011 | 19.01% | 27.48% | 0.60x | 1.15x | CN¥192.02 Million |
| 2012 | 24.39% | 34.73% | 0.61x | 1.14x | CN¥374.77 Million |
| 2013 | 26.54% | 35.68% | 0.64x | 1.16x | CN¥517.48 Million |
| 2014 | 27.58% | 36.16% | 0.62x | 1.22x | CN¥664.34 Million |
| 2015 | 27.58% | 36.40% | 0.65x | 1.17x | CN¥806.97 Million |
| 2016 | 26.05% | 36.43% | 0.59x | 1.22x | CN¥860.38 Million |
| 2017 | 23.99% | 34.95% | 0.61x | 1.13x | CN¥846.59 Million |
| 2018 | 21.89% | 31.35% | 0.59x | 1.19x | CN¥792.13 Million |
| 2019 | 11.02% | 16.00% | 0.58x | 1.19x | CN¥66.26 Million |
| 2020 | 1.10% | 2.22% | 0.40x | 1.26x | CN¥-489.97 Million |
| 2021 | 6.64% | 17.45% | 0.33x | 1.15x | CN¥-269.65 Million |
| 2022 | 8.02% | 18.30% | 0.36x | 1.23x | CN¥-156.98 Million |
| 2023 | 7.23% | 17.24% | 0.36x | 1.17x | CN¥-221.83 Million |
| 2024 | 6.90% | 14.99% | 0.38x | 1.20x | CN¥-269.65 Million |
Industry Comparison
This section compares Shenzhen Salubris Pharmaceuticals Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,523,155,599
- Average return on equity (ROE) among peers: -21.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals Co Ltd (002294) | CN¥8.93 Billion | 32.16% | 0.23x | $3.32 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $52.15 Million | 21.80% | 0.58x | $623.66 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $765.24 Million | 1.30% | 0.72x | $325.92 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $78.32 Million | 0.00% | 1.98x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $1.24 Billion | 8.20% | 0.96x | $1.75 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $38.34 Billion | 14.39% | 0.44x | $5.59 Billion |
| Hainan Haiyao Co Ltd (000566) | $590.38 Million | -258.34% | 9.36x | $713.60 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $184.11 Million | -46.59% | 2.19x | $317.60 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.57 Billion | 22.73% | 1.61x | $426.40 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $2.06 Billion | 23.61% | 0.46x | $2.04 Billion |
| Renhe Pharmacy Co Ltd (000650) | $338.74 Million | 2.59% | 1.24x | $777.45 Million |